Particle.news
Download on the App Store

Multiple Firms Vie to Lead Securities Suit Over ADMA Biologics

The chosen lead plaintiff will shape discovery into alleged undisclosed related‑party sales and revenue inflation after a March short‑seller report.

Overview

  • Several national plaintiff firms have filed securities complaints and are actively soliciting ADMA investors to seek lead‑plaintiff status ahead of an August 10, 2026 deadline.
  • The complaints accuse ADMA of using an undisclosed related‑party distributor, inflating revenue through channel stuffing, and maintaining weak internal controls that allegedly rendered public statements misleading.
  • A Culper Research short‑seller report on March 24, 2026 alleged channel stuffing, rebates and a related‑party distributor and preceded a roughly 31.6% combined stock decline over March 24–25 with further losses on March 26.
  • The case is at an early procedural stage in federal court in the District of New Jersey; no class has been certified and the firms’ allegations remain unproven pending discovery and court rulings.
  • Firms are also soliciting whistleblowers and pointing to the SEC whistleblower program, and the outcome of the lead‑plaintiff fight will determine who directs litigation strategy and potential investor recoveries.